{"title":"Deciphering the Role of Various Signaling Pathways in the Pathophysiology of Depression","authors":"Etash Vashisht, Vishal Vats, Ravinder Verma, Jatin Parashar, Vandana Garg, Rohit Dutt, Vineet Mittal, Govind Singh, Deepak Kaushik","doi":"10.2174/0115743624255521230920070219","DOIUrl":"https://doi.org/10.2174/0115743624255521230920070219","url":null,"abstract":"Background: Depression is one of the leading causes of disability around the globe. In the early years of depression, it is hypothesized that neurotransmitters have a major or dominant role in depression pathophysiology. The roles of different parts of the brain and neurotransmitters have emerged at different intervals of time, and various hypotheses beyond monoamines have arisen. In this review, numerous theories that have been proposed in the last 60 years are covered based on the literature. Methodology: This review was prepared with literature and data presented from different databases including PubMed, Frontier in Pharmacology, Elsevier, Journal of Depression and Anxiety, etc. Results: The different hypotheses of depression have been presented in different eras. Each hypothesis of depression tries to explore different aspects of depression, which shifts the pathogenesis of depression approaches towards bio-molecule and genetic roles. Conclusion: The pathophysiology of depression is very complex. None of the hypotheses alone can explain the pathophysiology of depression. All of these hypotheses are interconnected with each other. Through these hypotheses, it can be concluded that neuro-inflammation can be the base of depression and by reducing this factor we can overcome this problem","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135546036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An Identification of RET inhibitor: A Computational Study","authors":"A. Verma, P. Wadhwa","doi":"10.2174/1574362418666230817100406","DOIUrl":"https://doi.org/10.2174/1574362418666230817100406","url":null,"abstract":"\u0000\u0000RET (Rearranged during transcription) kinase is one of the key targets for anticancer drug development. Understanding the real mechanism of pharmacological action is aided by the protein-ligand interaction. The purpose of this study is to find the most effective RET inhibitors.\u0000\u0000\u0000\u0000Firstly, through a literature survey, we understood that tetrazole is useful nuclei to provide anticancer activity. Hence, a molecule was drawn containing tetrazole ring using Chemdraw 16.0. This drawn compound was used to determine further ligands employing Zincpharmer. Then, the 3D energy minimized structure of proposed ligands and positive control (selpercatinib and pralsetinib) were drawn using Chem3D. Further, docking was performed for all the ligands with phosphorylated RET kinase (PDB ID – 2IVU) using trial version of Molegro virtual docker 7.0.\u0000\u0000\u0000\u0000Determined ligands were docked with the help of Molegro virtual Docker (MVD) 7.0 employing RET kinase (2ivu) as protein.\u0000\u0000\u0000\u0000Top 10 compounds were selected and their drug-like properties along with their oral bioavailability were also determined. ZINC12180698, ZINC12180696, ZINC09616526, ZINC12180701, ZINC09616182, ZINC09616145, ZINC17052231, ZINC17052262, ZINC12180700, and ZINC09616518 were among the top ten compounds that showed the strongest affinity for the target for RET-mediated cancer in this study.\u0000","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41780607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Ali, Alwisha Lateef, Zuha Waheed, Mishal Waseem, Tahreem Zaheer, Miriam K Gomez, R. Blaheta, Saira Justin
{"title":"Mutation S249C of FGFR3b Promotes Bladder Cancer through Downstream\u0000Signaling Proteins FRS2 and FRS3: A Computational Approach","authors":"A. Ali, Alwisha Lateef, Zuha Waheed, Mishal Waseem, Tahreem Zaheer, Miriam K Gomez, R. Blaheta, Saira Justin","doi":"10.2174/1574362418666230810094626","DOIUrl":"https://doi.org/10.2174/1574362418666230810094626","url":null,"abstract":"\u0000\u0000Bladder cancer is the 9th most prevalent malignancy worldwide. Fibroblast\u0000Growth Factor Receptor 3b (FGFR3b), involved in cell proliferation, differentiation, and migration,\u0000is a mutations hotspot for bladder cancer with the most prevalent aberration being S249C.\u0000\u0000\u0000\u0000Impact of S249C of FGFR3b on bladder tumorigenesis via immediate downstream adapter\u0000proteins, Fibroblast Growth Factor Receptor Substrate (FRS2 and FRS3) is analyzed computationally.\u0000\u0000\u0000\u0000Wildtype FGFR3b monomer was modeled using I-TASSER and Phyre2. Whereas,\u0000S249C mutation was introduced via DynaMut. Wildtype FGFR3b homodimer and mutant heterodimer were structured and docked with downstream proteins using HADDOCK. PDBSum was\u0000used to study the amino acid residues involved in intermolecular and intramolecular interactions.\u0000\u0000\u0000\u0000Parameters of molecular flexibility and interatomic interactions predicted S249C heterodimer mutation of FGFR3b to be stable. Furthermore, docking with FRS2 protein revealed greater\u0000stability and higher binding affinity for S249C heterodimer mutant compared to wildtype homodimer. However, FRS3 docking showed a negligible decline in binding affinity for the S249C mutation but based on Van der Waal’s energy and insights into the interacting residues, it was revealed\u0000that these interactions might be stronger and for longer duration in comparison to the wildtype homodimer.\u0000\u0000\u0000\u0000S249C heterodimer mutation of FGFR3b is predicted to be stable with a tumorigenic\u0000potential where FRS2 and FRS3 might be among the key players of altered downstream signaling.\u0000Further investigations are required for a detailed picture.\u0000","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42422047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}